Literature DB >> 8093435

Relationship between IL-2 receptor expression and proliferative responses in lymphocytes from HIV-1 seropositive homosexual men.

R K Chopra1, N B Raj, J P Scally, A D Donnenberg, W H Adler, A J Saah, J B Margolick.   

Abstract

Previous studies have shown that exogenous IL-2 does not correct the reduction in phytohaemagglutinin (PHA)-induced proliferation of lymphocytes from HIV-1 infected (HIV+) individuals. We investigated the mechanism of this reduction to determine if reduced expression of the complete IL-2 receptor (IL-2R) was responsible. In a series of experiments, PHA-stimulated lymphocytes from a total of 89 HIV- and 93 HIV+ homosexual men from the Baltimore Multicentre AIDS Cohort Study (MACS) were studied to determine the expression of messages for the alpha and beta subunits of the IL-2R, the binding of 125I-IL-2 to high affinity IL-2R, and the effect of IL-2 on cell proliferation. Compared to HIV- donors, PHA-stimulated lymphocytes from most HIV+ donors demonstrated (i) a reduction in high affinity IL-2R expression that correlated with the reduction in the IL-2-induced proliferative response; and (ii) a reduction in expression of both IL-2R alpha- and beta-chain mRNA which may be responsible for decreased high affinity IL-2R expression. However, lymphocytes from some HIV+ individuals had borderline low IL-2-induced proliferation despite normal or elevated expression of high affinity IL-2R. These results suggest that decreased expression of IL-2R may account, at least in part, for the lower proliferative response of cells from HIV+ donors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8093435      PMCID: PMC1554661          DOI: 10.1111/j.1365-2249.1993.tb03347.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  41 in total

1.  Activation of peripheral blood T cells via the p75 interleukin 2 receptor.

Authors:  H Yagita; M Nakata; A Azuma; T Nitta; T Takeshita; K Sugamura; K Okumura
Journal:  J Exp Med       Date:  1989-10-01       Impact factor: 14.307

2.  Limiting dilution analysis of in vivo-activated (IL-2 responsive) peripheral blood lymphocytes in HIV-1-infected subjects.

Authors:  A D Donnenberg; J B Margolick; B F Polk
Journal:  Clin Immunol Immunopathol       Date:  1989-04

3.  Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA's.

Authors:  M Hatakeyama; M Tsudo; S Minamoto; T Kono; T Doi; T Miyata; M Miyasaka; T Taniguchi
Journal:  Science       Date:  1989-05-05       Impact factor: 47.728

4.  In vitro activation of T lymphocytes from HIV-seropositive blood donors. II. Decreased mitogen-induced expression of interleukin 2 receptor by both CD4 and CD8 cell subsets.

Authors:  H E Prince; C D Czaplicki
Journal:  Clin Immunol Immunopathol       Date:  1988-08

5.  Characterization of the interleukin 2 receptor beta chain using three distinct monoclonal antibodies.

Authors:  M Tsudo; F Kitamura; M Miyasaka
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

6.  Detection of lymphocytes expressing human T-lymphotropic virus type III in lymph nodes and peripheral blood from infected individuals by in situ hybridization.

Authors:  M E Harper; L M Marselle; R C Gallo; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

7.  Soluble interleukin 2 receptors released from mitogen stimulated human peripheral blood lymphocytes bind interleukin 2 and inhibit IL2 dependent cell proliferation.

Authors:  R K Chopra; D C Powers; N E Kendig; W H Adler; J E Nagel
Journal:  Immunol Invest       Date:  1989-10       Impact factor: 3.657

8.  Differential expression of the IL-2 receptor subunits, p55 and p75 on various populations of primary peripheral blood mononuclear cells.

Authors:  Y Ohashi; T Takeshita; K Nagata; S Mori; K Sugamura
Journal:  J Immunol       Date:  1989-12-01       Impact factor: 5.422

9.  Integrated proviral human immunodeficiency virus type 1 is present in CD4+ peripheral blood lymphocytes in healthy seropositive individuals.

Authors:  M C Psallidopoulos; S M Schnittman; L M Thompson; M Baseler; A S Fauci; H C Lane; N P Salzman
Journal:  J Virol       Date:  1989-11       Impact factor: 5.103

10.  Activation of natural killer cells via the p75 interleukin 2 receptor.

Authors:  J H Phillips; T Takeshita; K Sugamura; L L Lanier
Journal:  J Exp Med       Date:  1989-07-01       Impact factor: 14.307

View more
  5 in total

1.  CD8 T-cell proliferative capacity is compromised in primary HIV-1 infection.

Authors:  Sonya L Heath; Steffanie Sabbaj; Anju Bansal; J Michael Kilby; Paul A Goepfert
Journal:  J Acquir Immune Defic Syndr       Date:  2011-03-01       Impact factor: 3.731

2.  Regulatory dysfunction of the interleukin-2 receptor during HIV infection and the impact of triple combination therapy.

Authors:  D David; L Bani; J L Moreau; M P Treilhou; T Nakarai; M Joussemet; J Ritz; B Dupont; G Pialoux; J Thèze
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-15       Impact factor: 11.205

3.  Human immunodeficiency virus-1 envelope glycoproteins and anti-CD4 antibodies inhibit interleukin-2-induced Jak/STAT signalling in human CD4 T lymphocytes.

Authors:  M Kryworuchko; V Pasquier; J Thèze
Journal:  Clin Exp Immunol       Date:  2003-03       Impact factor: 4.330

4.  Late expression of granulysin by microbicidal CD4+ T cells requires PI3K- and STAT5-dependent expression of IL-2Rbeta that is defective in HIV-infected patients.

Authors:  Chun Fu Zheng; Gareth J Jones; Meiqing Shi; Jeremy C D Wiseman; Kaleb J Marr; Byron M Berenger; Shaunna M Huston; M John Gill; Alan M Krensky; Paul Kubes; Christopher H Mody
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

5.  Expression of the activation antigen CD69 predicts functionality of in vitro expanded peripheral blood mononuclear cells (PBMC) from healthy donors and HIV-infected patients.

Authors:  S D Nielsen; P Afzelius; A K Ersbøll; J O Nielsen; J E Hansen
Journal:  Clin Exp Immunol       Date:  1998-10       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.